FMG Pharma Pipeline
A disciplined pathway from discovery to product,
designed to translate science into measurable outcomes
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG001
Preclinical
Metabolic dysfunction associated steatotic liver disease (MASLD/MASH)
FMG001 is a new chemical entity (NCE) derived from FMG’s proprietary epicatechin technology. It is in preclinical development as a small-molecule candidate targeting metabolic dysfunctionassociated steatotic liver disease (MASLD/MASH).
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG002
Preclinical
Cutaneous complications of diabetes (diabetic dermatology / wound healing)
FMG002 is a new chemical entity (NCE) developed as a topical formulation from FMG’s proprietary epicatechinderived platform. It is in preclinical development for cutaneous complications associated with diabetes, including challenges in wound healing.
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG003
Preclinical
Dyslipidemia and cardiometabolic disease
FMG003 is an oral preclinical candidate based on FMG’s proprietary epicatechinderived technology. It is in development for dyslipidemia and associated cardiometabolic conditions.
Nutraceutical Portfolio
Every formula draws from peer-reviewed research on mitochondrial function, NAD+, oxidative stress, and bioenergetics.
Mitozz
Mitozz is a dietary supplement formulated around highly purified (-)-epicatechin to support mitochondrial health, cellular energy, and healthy aging. It is designed for people looking to support the body’s natural energy systems with a science-focused nutraceutical approach.
Backed by over 60 published studies from our team
